Target Name: USP10
NCBI ID: G9100
Review Report on USP10 Target / Biomarker Content of Review Report on USP10 Target / Biomarker
USP10
Other Name(s): Ubiquitin-specific-processing protease 10 | KIAA0190 | UBP10_HUMAN | USP10 variant 2 | ubiquitin specific peptidase 10 | Ubiquitin carboxyl-terminal hydrolase 10 | Deubiquitinating enzyme 10 | ubiquitin carboxyl-terminal hydrolase 10 | ubiquitin-specific-processing protease 10 | ubiquitin specific protease 10 | Ubiquitin carboxyl-terminal hydrolase 10 (isoform 2) | Ubiquitin thioesterase 10 | ubiquitin thioesterase 10 | UBPO | deubiquitinating enzyme 10 | ubiquitin thiolesterase 10 | Ubiquitin specific peptidase 10, transcript variant 2

USP10: A Potential Drug Target and Biomarker for Ubiquitin-Specific Processing Protease 10

Ubiquitin (Upp) is a protein that plays a critical role in the regulation of protein stability and dynamics. It is a small molecule that functions as a linker, helping to connect and stabilize proteins. Ubiquitin is involved in a wide range of cellular processes, including DNA replication, gene expression, and cell signaling. The protein Ubiquitin-specific processing protease 10 (USP10) is a key enzyme that modifies the stability and activity of Ubiquitin.

USP10 is a 21-kDa protein that is expressed in most tissues and cells. It is highly conserved, with a calculated pI of 6.9 and a predicted localization in the cytoplasm. USP10 is involved in the degradation of Ubiquitin, which is a target for many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Drug Target Potential

The potential drug target for USP10 is its role in Ubiquitin degradation. USP10 is involved in the degradation of Ubiquitin, which is a known risk factor for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The degradation of Ubiquitin by USP10 could be targeted as a potential therapeutic approach for these diseases.

One approach to targeting USP10 is to inhibit its activity by introducing small molecules that interfere with its catalytic activity. Such small molecules could be designed to specifically target the active site of USP10, which is located at its N-terminus. This would result in a decrease in the activity of USP10 and a corresponding decrease in the degradation of Ubiquitin.

Biomarker Potential

Another approach to targeting USP10 is to use it as a biomarker for disease diagnosis or monitoring. The degradation of Ubiquitin by USP10 is a well-established process that can be used as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One approach to using USP10 as a biomarker is to measure the levels of Ubiquitin in the cells or tissues of individuals with the disease. The levels of Ubiquitin can be used to indicate the level of USP10 activity and, therefore, the level of disease severity. This approach could be used to monitor the effectiveness of a potential therapeutic intervention in individuals with cancer, neurodegenerative diseases, or autoimmune disorders.

Conclusion

USP10 is a protein that plays a critical role in the regulation of Ubiquitin, a protein that is involved in a wide range of cellular processes. The degradation of Ubiquitin by USP10 is a well-established process that can be used as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The potential drug target for USP10 is its role in Ubiquitin degradation, and the potential biomarker for USP10 is its ability to be used to monitor the levels of Ubiquitin in cells or tissues of individuals with the disease. Further research is needed to fully understand the role of USP10 in disease and to develop effective therapeutic interventions.

Protein Name: Ubiquitin Specific Peptidase 10

Functions: Hydrolase that can remove conjugated ubiquitin from target proteins such as p53/TP53, BECN1, SNX3 and CFTR. Acts as an essential regulator of p53/TP53 stability: in unstressed cells, specifically deubiquitinates p53/TP53 in the cytoplasm, leading to counteract MDM2 action and stabilize p53/TP53. Following DNA damage, translocates to the nucleus and deubiquitinates p53/TP53, leading to regulate the p53/TP53-dependent DNA damage response. Component of a regulatory loop that controls autophagy and p53/TP53 levels: mediates deubiquitination of BECN1, a key regulator of autophagy, leading to stabilize the PIK3C3/VPS34-containing complexes. In turn, PIK3C3/VPS34-containing complexes regulate USP10 stability, suggesting the existence of a regulatory system by which PIK3C3/VPS34-containing complexes regulate p53/TP53 protein levels via USP10 and USP13. Does not deubiquitinate MDM2. Deubiquitinates CFTR in early endosomes, enhancing its endocytic recycling. Involved in a TANK-dependent negative feedback response to attenuate NF-kappaB activation via deubiquitinating IKBKG or TRAF6 in response to interleukin-1-beta (IL1B) stimulation or upon DNA damage (PubMed:25861989). Deubiquitinates TBX21 leading to its stabilization (PubMed:24845384)

The "USP10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

USP11 | USP12 | USP12-AS1 | USP12-DT | USP13 | USP14 | USP15 | USP16 | USP17L1 | USP17L10 | USP17L11 | USP17L12 | USP17L13 | USP17L14P | USP17L15 | USP17L17 | USP17L18 | USP17L2 | USP17L20 | USP17L21 | USP17L24 | USP17L25 | USP17L26 | USP17L27 | USP17L29 | USP17L3 | USP17L5 | USP17L6P | USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6